madrigal pharmaceuticals inc. is a biotechnology company based out of calle laguna del marquesado nª 19, nave 16 edificio adriana 1ª planta, polígono industrial la resina (villaverde), madrid, community of madrid, spain.
![Madrigal Pharmaceuticals logo](/files/LOGO/1157601-MDGL.png)
Company profile
Ticker
MDGL
Exchange
Website
CEO
Rebecca Taub
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
SYNTA PHARMACEUTICALS CORP
SEC CIK
Corporate docs
Subsidiaries
Madrigal Pharmaceuticals EU Limited, an Ireland company • Synta Limited Incorporated • Canticle Pharmaceuticals, Inc. ...
MDGL stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
7 May 24
424B3
Prospectus supplement
7 May 24
424B5
Prospectus supplement for primary offering
7 May 24
S-3ASR
Automatic shelf registration
7 May 24
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
7 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
8-K
Other Events
2 Apr 24
Latest ownership filings
4
Robert E. Waltermire
18 Jun 24
4
Robert E. Waltermire
14 Jun 24
144
Notice of proposed sale of securities
14 Jun 24
144
Notice of proposed sale of securities
14 Jun 24
4
FRED B CRAVES
13 Jun 24
144
Notice of proposed sale of securities
13 Jun 24
144
Notice of proposed sale of securities
12 Jun 24
144
Notice of proposed sale of securities
11 Jun 24
144
Notice of proposed sale of securities
6 Jun 24
4
Robert E. Waltermire
23 May 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 622.52 mm | 622.52 mm | 622.52 mm | 622.52 mm | 622.52 mm | 622.52 mm |
Cash burn (monthly) | (no burn) | (no burn) | 50.68 mm | 37.85 mm | 49.72 mm | 32.44 mm |
Cash used (since last report) | n/a | n/a | 136.06 mm | 101.62 mm | 133.48 mm | 87.10 mm |
Cash remaining | n/a | n/a | 486.46 mm | 520.90 mm | 489.03 mm | 535.42 mm |
Runway (months of cash) | n/a | n/a | 9.6 | 13.8 | 9.8 | 16.5 |
Institutional ownership, Q1 2024
96.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 270 |
Opened positions | 127 |
Closed positions | 27 |
Increased positions | 63 |
Reduced positions | 51 |
13F shares | Current |
---|---|
Total value | 5.19 tn |
Total shares | 20.63 mm |
Total puts | 1.04 mm |
Total calls | 821.00 k |
Total put/call ratio | 1.3 |
Largest owners | Shares | Value |
---|---|---|
JHG Janus Henderson | 2.60 mm | $694.53 bn |
Baker Bros. Advisors | 1.97 mm | $526.01 bn |
Avoro Capital Advisors | 1.94 mm | $519.24 bn |
Paulson & Co. | 1.78 mm | $474.00 bn |
Vanguard | 1.67 mm | $445.64 bn |
BLK Blackrock | 1.21 mm | $323.22 bn |
T. Rowe Price | 803.21 k | $214.49 mm |
FMR | 713.91 k | $190.64 bn |
STT State Street | 624.94 k | $166.88 bn |
Perceptive Advisors | 429.95 k | $114.81 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Jun 24 | Robert E. Waltermire | Common Stock | Sell | Dispose S | No | No | 280 | 1,900 | 532.00 k | 5,500 |
14 Jun 24 | Robert E. Waltermire | Common Stock | Option exercise | Acquire M | No | No | 87.09 | 1,900 | 165.47 k | 7,400 |
14 Jun 24 | Robert E. Waltermire | Stock Option Common Stock | Option exercise | Dispose M | No | No | 87.09 | 1,900 | 165.47 k | 10,350 |
12 Jun 24 | Robert E. Waltermire | Common Stock | Sell | Dispose S | No | No | 285 | 2,000 | 570.00 k | 5,500 |
12 Jun 24 | Robert E. Waltermire | Common Stock | Option exercise | Acquire M | No | No | 87.92 | 2,000 | 175.84 k | 7,500 |
12 Jun 24 | Robert E. Waltermire | Stock Option Common Stock | Option exercise | Dispose M | No | No | 87.92 | 2,000 | 175.84 k | 15,200 |
11 Jun 24 | Craves Fred B | Common Stock | Gift | Dispose G | Yes | No | 0 | 45,852 | 0.00 | 11,210 |
11 Jun 24 | Craves Fred B | Common Stock | Gift | Dispose G | No | No | 0 | 39,000 | 0.00 | 374,362 |
21 May 24 | Robert E. Waltermire | Common Stock | Sell | Dispose S | No | No | 231.34 | 1,036 | 239.67 k | 5,500 |
14 May 24 | Craves Fred B | Common Stock | Sell | Dispose S | No | Yes | 219.9 | 100 | 21.99 k | 413,362 |
News
Wolfe Research Initiates Coverage On Madrigal Pharmaceuticals with Outperform Rating
11 Jun 24
10 Health Care Stocks With Whale Alerts In Today's Session
11 Jun 24
Madrigal Pharmaceuticals Announces New Analyses From Phase 3 MAESTRO-NASH Trial Of Resmetirom To Be Presented At EASL Congress, June 5-8, 2024 In Milan, Italy
6 Jun 24
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
5 Jun 24
DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
5 Jun 24